Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen Idec 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen Idec 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec

3Q Revenues: $1.1 billion (+38%)

3Q Earnings: $207 million (+74%)

YTD Revenues: $3.0 billion (+33%)

YTD Earnings: $576.5 million (+32%)

Comments: Tysabri sales recorded by Biogen, based on its collaboration with Elan, were $171 million (+172%) in the quarter. This consisted of $56 million related to product sold through Elan in the U.S. (based on $122 million of in-market sales); and $115 million related to product sold by Biogen internationally. Avonex sales were up 26% to $573 million. Rituxan sales were up 27% to $299 million (co-marketed in the U.S. with Genentech). R&D expenses were $269 million in the quarter (-6%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters